investments

Since 2008, Yazbeck Investments has assessed the risks associated with hundreds of potential projects, successfully investing, operating and securing exits for various asset backed investments made in the real estate lending and development, underground construction, and healthcare & technology fields.

Since 2013, Yazbeck Investments has focused on the Legal Cannabis Industry, making strategic investments and securing exits in the cultivation, manufacturing, distribution, retail and technology sectors of the space.

Since 2022, Yazbeck Investments has focussed on the pharmaceutical industry, supporting leading companies developing biotherapeutic medications which have shown to be superior to traditional small molecule medicines.  

Current Healthcare Portfolio

Tillat Pharmaceuticals in 2023 – Tillat is a pharmaceutical company that manufactures and commercializes high demand, halal-compliant medications to an array of countries worldwide. Currently, Tillat has a pipeline of 16 halal medications (8 biological and 8 chemical) at various stages of development. The company expects a majority of these medications to be available globally in 2H24.

Antharis Therapeutics in 2022 – Antharis is biopharmaceutical company developing a leading portfolio of cancer and neurology related immuno-therapeutics. Yazbeck Investments helped Antharis complete its Series A round which placed the company at the leading edge of biotechnology companies generating high-potential biologic assets for the treatment of significant diseases in multiple therapeutic classes.

 

Past Cannabis Investments

mydx-logo-ticker-2

MyDx in 2013 – a leader in cannabis health technology tracking the science of how cannabis makes people feel. Mr. Yazbeck founded, seeded the capital for, took the company public, and successfully developed the product and created a market for the first handheld chemical analyzer for cannabis consumers. 

Ebbu in 2014 – Yazbeck Investments was one of the first investors in Ebbu, a leader in hemp research acquired in 2018 for $330 million by Canopy Growth Corporation.

 

mjic_logo_tagline-1-1-e1442166106492

Manifest 7 in 2015 – Yazbeck Investments was an early investor in MJIC, later acquired by Manifest Seven, a cannabis retail and distribution company in California which went public in2020 on the Canadian Stock Exchange.

Ramona Cannabis Company in 2020 – a San Diego county licensed and vertically integrated cannabis company currently operating a profitable retail dispensary and delivery service, a manufacturing and co-packing facility, a distribution hub, and is licensed for cannabis cultivation.

 

Global Cannabis Legalization Efforts

 Since 2018, Mr. Yazbeck has been working closely with local Lebanese scientists, business leaders, activists and government regulators to help draft and pass a law to Legalize Cannabis in Lebanon. On April 21, 2020, Lebanon passed legislation legalizing medical cannabis cultivation in the country.

 
 

 

Future Investments
 
Since 2024, Yazbeck Investments, with the onboarding of Mr. Jason Laba, became Yazbeck & Co., and has expanded its focus to the following industries: 
 

Pharmaceutical/Healthcare
Real Estate
Agriculture
Advanced Technologies
Clean Energy
Entertainment
Humanitarian Initiatives